Zobrazeno 1 - 10
of 1 822
pro vyhledávání: '"classical Hodgkin lymphoma"'
Autor:
José L. Solórzano, Victoria Menéndez, Edwin Parra, Luisa Solis, Ruth Salazar, Mónica García-Cosío, Fina Climent, Sara Fernández, Eva Díaz, Alejandro Francisco-Cruz, Joseph Khoury, Mei Jiang, Auriole Tamegnon, Carlos Montalbán, Ignacio Melero, Ignacio Wistuba, Carlos De Andrea, Juan F. García
Publikováno v:
OncoImmunology, Vol 13, Iss 1 (2024)
The Hodgkin and Reed – Sternberg (HRS) cells in classical Hodgkin Lymphoma (cHL) actively modify the immune tumor microenvironment (TME) attracting immunosuppressive cells and expressing inhibitory molecules. A high frequency of myeloid cells in th
Externí odkaz:
https://doaj.org/article/eca23b7e29a44b36a41152a418b1a45b
Autor:
Edoardo Ruggeri, Federica Frezzato, Nayla Mouawad, Marco Pizzi, Federico Scarmozzino, Guido Capasso, Valentina Trimarco, Laura Quotti Tubi, Alessandro Cellini, Chiara Adele Cavarretta, Valeria Ruocco, Andrea Serafin, Francesco Angotzi, Nicolò Danesin, Sabrina Manni, Monica Facco, Francesco Piazza, Livio Trentin, Andrea Visentin
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionIn classical Hodgkin lymphoma (cHL), the survival of neoplastic cells is mediated by the activation of NF-κB, JAK/STAT and PI3K/Akt signaling pathways. CK2 is a highly conserved serine/threonine kinase, consisting of two catalytic (α) a
Externí odkaz:
https://doaj.org/article/fb28e6558d64433d9e366831a9784f2f
Publikováno v:
eJHaem, Vol 4, Iss 4, Pp 908-911 (2023)
Abstract Optimal management of patients who present with Hodgkin lymphoma continues to evolve. Most patients are cured with current treatment strategies, some but both short and long‐term morbidity and mortality from treatment have particular relev
Externí odkaz:
https://doaj.org/article/ade80093c1fe4515aff0d3fdcb988fcf
Autor:
Abdulaziz A. Aloliqi
Publikováno v:
Molecules, Vol 29, Iss 15, p 3476 (2024)
Classical Hodgkin lymphoma (cHL) is a common B-cell cancer and a significant health concern, especially in Western and Asian countries. Despite the effectiveness of chemotherapy, many relapse cases are being reported, highlighting the need for improv
Externí odkaz:
https://doaj.org/article/a43a861033ff423d84d3d9256e340f00
Autor:
M. R. Matushchak, H. L. Panfilova
Publikováno v:
Фармацевтичний журнал, Vol 3, Pp 68-81 (2023)
The use of new chemotherapy regimens for Hodgkin lymphoma, containing immunotherapeutic drugs, such as brentuximab vedotin, is an urgent direction in the development of modern oncohematology. The inclusion of these drugs in programs of financial supp
Externí odkaz:
https://doaj.org/article/90eae1cabdd749e6b83fb8d4ddeadf7b
Autor:
Chen Zhang, Jili Deng, Yan Xie, Lan Mi, Weiping Liu, Xiaopei Wang, Linjun Zhao, Yuqin Song, Jun Zhu
Publikováno v:
Cancer Medicine, Vol 12, Iss 9, Pp 10351-10362 (2023)
Abstract Background Autologous stem cell transplantation (ASCT) is the standard treatment strategy for refractory or relapsed classical Hodgkin lymphoma (R/R cHL). However, a single transplantation is insufficient to cure the disease because of unfav
Externí odkaz:
https://doaj.org/article/2324eeada9cd4bddb93f9f17f764330e
Autor:
Chunmeng Wang, Yuting Pan, Yang Liu, Bing Guo, Jinhong Shi, Guanghua Rong, Zhipeng Guo, Zhifang Li, Qingming Yang, Jing Nie, Weidong Han
Publikováno v:
MedComm, Vol 4, Iss 6, Pp n/a-n/a (2023)
Abstract Patients with relapsed/refractory classical Hodgkin lymphoma (cHL) achieve complete response (CR) after decitabine‐plus‐camrelizumab therapy, while long‐term outcome especially after treatment discontinuation remains unclear. We presen
Externí odkaz:
https://doaj.org/article/1e30c08be0a246dc86f77418e618d393
Autor:
Pieter F. de Groot, Arjan J. Kwakernaak, Ester M. M. van Leeuwen, Rosalina M. L. van Spaendonk, Evert-Jan Kooi, Daphne de Jong, Taco W. Kuijpers, Josée M. Zijlstra, Godelieve J. de Bree
Publikováno v:
Frontiers in Medicine, Vol 10 (2023)
Here we present the case of a 28-year-old man with X-linked immunodeficiency with magnesium defect, Epstein–Barr virus (EBV) infection and neoplasia (XMEN) disease. He presented with immune thrombocytopenia within 1 year after successful autologous
Externí odkaz:
https://doaj.org/article/597b8503eafe4290bec7cd6dc7af646d
Autor:
Matteo D'Addona, Luca Pezzullo, Corradino Campisi, Corrado Cesare Campisi, Valentina Giudice, Vincenzo Ciccone, Roberto Guariglia, Bianca Serio, Carmine Selleri
Publikováno v:
Mediterranean Journal of Hematology and Infectious Diseases, Vol 15, Iss 1 (2023)
Externí odkaz:
https://doaj.org/article/e7ed165bc4104a12b96d8a0a286d9865
Autor:
Tianyu Yang, Shuang Liu, Rui Zuo, Hongwei Liang, Lu Xu, Zhengjie Wang, Xiaoliang Chen, Hua Pang
Publikováno v:
BMC Medical Imaging, Vol 23, Iss 1, Pp 1-12 (2023)
Abstract Background The combination of anti-programmed death-1 antibodies and chemotherapy is effective; however, there are no reliable outcome prediction factors. We investigated the prognostic factors based on 18Fluorine-fluorodeoxyglucose positron
Externí odkaz:
https://doaj.org/article/29e07c25a5d64013b2c3257bd81f19fa